Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma

Mostrar otras versiones (1)

Immune-checkpoint inhibitors are emerging as revolutionary drugs for certain malignancies. However, blocking the co-inhibitory signals may lead to immune-related adverse events, mainly in the spectrum of autoimmune diseases including colitis, endocrinopathies and nephritis. Here, we report a case of...

Descripción completa

Detalles Bibliográficos
Autores principales: Murakami, Naoka, Borges, Thiago J., Yamashita, Michifumi, Riella, Leonardo V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Onconephrology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886917/
https://www.ncbi.nlm.nih.gov/pubmed/27274826
http://dx.doi.org/10.1093/ckj/sfw024
_version_ 1782434666845831168
author Murakami, Naoka
Borges, Thiago J.
Yamashita, Michifumi
Riella, Leonardo V.
author_facet Murakami, Naoka
Borges, Thiago J.
Yamashita, Michifumi
Riella, Leonardo V.
author_sort Murakami, Naoka
collection PubMed
description Immune-checkpoint inhibitors are emerging as revolutionary drugs for certain malignancies. However, blocking the co-inhibitory signals may lead to immune-related adverse events, mainly in the spectrum of autoimmune diseases including colitis, endocrinopathies and nephritis. Here, we report a case of a 75-year-old man with metastatic malignant melanoma treated with a combination of nivolumab (anti-PD1-antibody) and ipilimumab (anti-CTLA-4 antibody) who developed systemic rash along with severe acute tubulointerstitial nephritis after two doses of combination therapy. Kidney biopsy and peripheral blood immune profile revealed highly proliferative and cytotoxic T cell features. Herein, we discuss the pathophysiology and management of immune checkpoint blockade-related adverse events.
format Online
Article
Text
id pubmed-4886917
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-48869172016-06-03 Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma Murakami, Naoka Borges, Thiago J. Yamashita, Michifumi Riella, Leonardo V. Clin Kidney J Onconephrology Immune-checkpoint inhibitors are emerging as revolutionary drugs for certain malignancies. However, blocking the co-inhibitory signals may lead to immune-related adverse events, mainly in the spectrum of autoimmune diseases including colitis, endocrinopathies and nephritis. Here, we report a case of a 75-year-old man with metastatic malignant melanoma treated with a combination of nivolumab (anti-PD1-antibody) and ipilimumab (anti-CTLA-4 antibody) who developed systemic rash along with severe acute tubulointerstitial nephritis after two doses of combination therapy. Kidney biopsy and peripheral blood immune profile revealed highly proliferative and cytotoxic T cell features. Herein, we discuss the pathophysiology and management of immune checkpoint blockade-related adverse events. Oxford University Press 2016-06 2016-05-04 /pmc/articles/PMC4886917/ /pubmed/27274826 http://dx.doi.org/10.1093/ckj/sfw024 Text en © The Author 2016. Published by Oxford University Press on behalf of ERAEDTA http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Onconephrology
Murakami, Naoka
Borges, Thiago J.
Yamashita, Michifumi
Riella, Leonardo V.
Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
title Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
title_full Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
title_fullStr Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
title_full_unstemmed Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
title_short Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
title_sort severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
topic Onconephrology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886917/
https://www.ncbi.nlm.nih.gov/pubmed/27274826
http://dx.doi.org/10.1093/ckj/sfw024
work_keys_str_mv AT murakaminaoka severeacuteinterstitialnephritisaftercombinationimmunecheckpointinhibitortherapyformetastaticmelanoma
AT borgesthiagoj severeacuteinterstitialnephritisaftercombinationimmunecheckpointinhibitortherapyformetastaticmelanoma
AT yamashitamichifumi severeacuteinterstitialnephritisaftercombinationimmunecheckpointinhibitortherapyformetastaticmelanoma
AT riellaleonardov severeacuteinterstitialnephritisaftercombinationimmunecheckpointinhibitortherapyformetastaticmelanoma

Ejemplares similares